Summary: CAR-T cell therapy is a promising new treatment for multiple myeloma. This presentation describes the versions of this therapy that are currently available, their potential complications and side effects, and the risk/benefit calculations in deciding when this treatment is appropriate.
Presenter: Gunjan Shah MD, MS, Memorial Sloan Kettering Cancer Center
To read the transcript, go to:
[ Ссылка ]
Highlights:
Treatments for multiple myeloma have expanded over several decades. Current treatments were only approved after 2000 and many clinical trials are exploring additional treatment options.
There are two current CAR T-cell products for multiple myeloma. They require patients to have had at least four prior lines of therapy. However, current clinical trials are investigating whether these treatments could be used earlier in the disease process.
Common side effects of CAR T-cell therapy are cytokine release syndrome and neurological toxicity, as well as infections.
April 2023, Part of the Virtual Celebrating a Second Chance at Life Survivorship Symposium
Presentation is 32 minutes long with 17 minutes of Q & A
Key Points:
(05:03): CAR T-cell treatment for multiple myeloma is now approved and approval for bispecific antibodies should be coming soon.
(08:39): CAR T-cell therapy uses the patient’s own T-cells that are removed, engineered to kill cancer cells, and returned to the patient’s body.
(09:20): Chemotherapy is used to make the patient’s body receptive to the CAR T-cells.
(11:00): CAR T-cells usually last at least a month in the patient’s body.
(17:48): In clinical trials, between 60% and 90% of patients with multiple myeloma have had some response to these treatments, and the treatments have worked for up to two years.
(19:51): The timing of side effects differs with each CAR T-cell product and must be monitored and treated accordingly.
(21:56): Patient-reported outcomes often describe fatigue, especially during the first month after CAR T-cell treatment, but it can last longer as well.
(23:40): CAR T-cell therapy is expensive but may be worth it because it works differently than all of the prior treatments patients typically receive.
(27:26): The possibility of using donor cells and its risks and benefits in CAR T-cell therapy is also being investigated.
(28:12): Two big concerns for patients interested in CAR T-cell treatments are insurance approval and timing.
Meet the speaker:
[ Ссылка ]
WHO WE ARE: BMT InfoNet is dedicated to providing patients and their loved ones with emotional support and high quality, easy-to-understand information about blood stem cell transplants (bone marrow, peripheral blood and cord blood) and other cellular therapies. Whether you are just beginning your transplant or cellular therapy journey, or learning to manage the joys and challenges of survivorship,
BMT InfoNet is here to help before, during and after treatment. Our goal is to empower you with credible information and emotional support, so that you can take a more active role in decisions affecting your health. [ Ссылка ]
VISIT US ON SOCIAL MEDIA:
[ Ссылка ]
[ Ссылка ]
[ Ссылка ]
[ Ссылка ]
[ Ссылка ]
